Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis

神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移

基本信息

  • 批准号:
    10222592
  • 负责人:
  • 金额:
    $ 34.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-31 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

SUMMARY Transforming growth factor beta receptor type I/II (TßRI/II) signaling is activated on the plasma membrane (PM) by ligand binding, inducing Smad3/4-dependent (canonical) or independent cell migration, invasion and/or metastasis. While Smad3/4 activates, Smad7 binds and inhibits TßRI/II signaling. Primary cilia are protrusions of PM that mediate cell-to-cell communication and migration/invasion without affecting cell motility by activating various signaling pathways such as sonic hedgehog (Shh). Ceramide is a bioactive sphingolipid with tumor suppressive signaling functions, and ceramide synthase 4 (CerS4) generates long chain C18/20- ceramide. However, any mechanistic link between ceramide metabolism, Smad7 recruitment and TßRI/II signaling at the primary cilium membrane for the regulation of tumor metastasis remains unknown. Based on our novel and unpublished preliminary data, we designed this application to test a novel hypothesis that CerS4/ceramide inhibits TßRI/II trafficking and signaling selectively at the primary cilia membrane via Smad7 to modulate cell migration, invasion and/or metastasis. The following Specific Aims are proposed: Aim 1) Define the mechanisms by which ceramide regulates TßRI/II signaling by Smad7; Aim 2) Determine the mechanisms by which ceramide/Smad7 inhibitory complex regulates TßRI/II trafficking to the primary cilia; and Aim 3) Dissect the downstream mechanism by which TßRI/II signaling at primary cilia induces tumor metastasis in response to alterations of the CerS4/ceramide/Smad7 axis. Overall, based on our expertise in cancer signaling and lipid metabolism, we are uniquely positioned to develop novel mechanism-based strategies for targeting/inhibiting TßRI/II signaling selectively in primary cilium, which then will help attenuate tumor metastasis without affecting canonical functions of TGF-ß signaling (reducing general toxicity), using innovative molecular/pharmacologic tools, genetic models, and clinical specimens.
总结 转化生长因子β受体I/II型(T β RI/II)信号在质膜上被激活 (PM)通过配体结合,诱导Smad 3/4依赖性(典型)或独立的细胞迁移,侵袭 和/或转移。当Smad 3/4激活时,Smad 7结合并抑制T β RI/II信号传导。初级纤毛 PM突起,介导细胞间通讯和迁移/侵袭,而不影响细胞运动性 通过激活各种信号通路,如音速刺猬(Shh)。神经酰胺是一种生物活性鞘脂 具有肿瘤抑制信号传导功能,神经酰胺合酶4(CerS 4)产生长链C18/20- 神经酰胺然而,神经酰胺代谢、Smad 7募集和T β RI/II之间的任何机制联系, 在初级纤毛膜上用于调节肿瘤转移的信号传导仍然未知。基于 我们的新的和未发表的初步数据,我们设计了这个应用程序来测试一个新的假设, CerS 4/神经酰胺通过Smad 7选择性抑制初级纤毛膜上的T β RI/II运输和信号传导 以调节细胞迁移、侵袭和/或转移。提出了以下具体目标: 定义神经酰胺通过Smad 7调节T β RI/II信号传导的机制;目的2)确定 神经酰胺/Smad 7抑制复合物调节T β RI/II向初级纤毛运输的机制;和 目的3)探讨初级纤毛T β RI/II信号转导诱导肿瘤的下游机制 CerS 4/神经酰胺/Smad 7轴的改变可导致肿瘤转移。总的来说,根据我们在以下方面的专业知识, 癌症信号传导和脂质代谢,我们处于独特的地位,开发新的机制为基础的 在初级纤毛中选择性靶向/抑制T β RI/II信号传导的策略, 肿瘤转移而不影响TGF-β信号传导的典型功能(降低一般毒性),使用 创新的分子/药理学工具、遗传模型和临床标本。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Besim Ogretmen其他文献

Besim Ogretmen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Besim Ogretmen', 18)}}的其他基金

Targeting AML Mitochondria by Ceramide
通过神经酰胺靶向 AML 线粒体
  • 批准号:
    10546239
  • 财政年份:
    2022
  • 资助金额:
    $ 34.2万
  • 项目类别:
Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging
鞘脂代谢和信号传导在衰老和衰老调节中的作用
  • 批准号:
    10253130
  • 财政年份:
    2020
  • 资助金额:
    $ 34.2万
  • 项目类别:
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy
头部调节中的神经酰胺信号传导
  • 批准号:
    9930853
  • 财政年份:
    2019
  • 资助金额:
    $ 34.2万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    10411382
  • 财政年份:
    2018
  • 资助金额:
    $ 34.2万
  • 项目类别:
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
神经酰胺代谢和 PD-L1 信号调节以控制 TNBC 的转移和免疫治疗耐药
  • 批准号:
    10801345
  • 财政年份:
    2018
  • 资助金额:
    $ 34.2万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    9977980
  • 财政年份:
    2018
  • 资助金额:
    $ 34.2万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    10460230
  • 财政年份:
    2018
  • 资助金额:
    $ 34.2万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    9441547
  • 财政年份:
    2018
  • 资助金额:
    $ 34.2万
  • 项目类别:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
通过靶向鞘脂信号传导开发新型癌症疗法
  • 批准号:
    9072008
  • 财政年份:
    2016
  • 资助金额:
    $ 34.2万
  • 项目类别:
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling
项目2:系统性S1P和补体信号调节肿瘤转移
  • 批准号:
    9072014
  • 财政年份:
    2016
  • 资助金额:
    $ 34.2万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 34.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了